Database Query Results : , , EZH2

EZH2, enhancer of zeste homolog 2 (Drosophila): Click to Expand ⟱
Source: CGL-Driver Genes
Type: Oncogene
EZH2 (Enhancer of Zeste Homolog 2) is a gene that encodes a protein which is a key component of the Polycomb Repressive Complex 2 (PRC2). This complex is involved in the regulation of gene expression through histone methylation, specifically the trimethylation of histone H3 at lysine 27 (H3K27me3), which leads to transcriptional repression of target genes.
EZH2 is often overexpressed in various types of cancers, including breast, prostate, and lymphoma. This overexpression can lead to the silencing of tumor suppressor genes, contributing to uncontrolled cell proliferation and survival.
EZH2 is biology-first; its biomarker value is a readout of epigenetic state.


Scientific Papers found: Click to Expand⟱
3435- aLinA,    Alpha-linolenic acid-mediated epigenetic reprogramming of cervical cancer cell lines
- in-vitro, Cerv, HeLa - in-vitro, Cerv, SiHa - in-vitro, Cerv, C33A
DNMTs↓, HDAC↓, HATs↑, hTERT/TERT↓, CDH1↑, RARβ↑, DNMT1↓, DNMT3A↓, TET2↑, HDAC1↓, HDAC8↓, SIRT1↓, HMTs↑, EZH2↓,
2631- Api,    Apigenin Induces Autophagy and Cell Death by Targeting EZH2 under Hypoxia Conditions in Gastric Cancer Cells
- in-vivo, GC, NA - in-vitro, GC, AGS
ER Stress↑, Hif1a↓, EZH2↓, HDAC↓, TumAuto↑, p‑mTOR↓, AMPKα↑, GRP78/BiP↑, ROS↑, MMP↓, Ca+2↑, ATF4↑, CHOP↑,
2703- BBR,  CUR,  SFN,  UA,  GamB  Naturally occurring anti-cancer agents targeting EZH2
- Review, Var, NA
EZH2↓,
2704- BBR,    Inhibitory Effect of Berberine on Zeste Homolog 2 (Ezh2) Enhancement in Human Esophageal Cell Lines
- in-vitro, ESCC, KYSE450
EZH2↓, AXL↓,
2688- CUR,    Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs
- Review, Var, NA - Review, AD, NA
*ROS↓, *SOD↑, p16↑, JAK2↓, STAT3↓, CXCL12↓, IL6↓, MMP2↓, MMP9↓, TGF-β↓, α-SMA↓, LAMs↓, DNAdam↑, *memory↑, *cognitive↑, *Inflam↓, *antiOx↑, *NO↑, *MDA↓, *ROS↓, DNMT1↓, ROS↑, Casp3↑, Apoptosis↑, miR-21↓, LC3II↓, ChemoSen↑, NF-kB↓, CSCs↓, Nanog↓, OCT4↓, SOX2↓, eff↑, Sp1/3/4↓, miR-27a-3p↓, ZBTB10↑, SOX9?, ChemoSen↑, VEGF↓, XIAP↓, Bcl-2↓, cycD1/CCND1↓, BioAv↑, Hif1a↓, EMT↓, BioAv↓, PTEN↑, VEGF↓, Akt↑, EZH2↓, NOTCH1↓, TP53↑, NQO1↑, HO-1↑,
417- CUR,    Curcumin inhibits the growth of triple‐negative breast cancer cells by silencing EZH2 and restoring DLC1 expression
- vitro+vivo, BC, MCF-7 - vitro+vivo, BC, MDA-MB-231 - vitro+vivo, BC, MDA-MB-468
EZH2↓, DLC1↑, cycA1/CCNA1↓, CDK1↓, Bcl-2↓, Casp9↑, DLC1↑,
679- EGCG,  5-FU,    Epigallocatechin-3-gallate targets cancer stem-like cells and enhances 5-fluorouracil chemosensitivity in colorectal cancer
- in-vitro, CRC, NA
NOTCH1↓, BMI1↓, SUZ12↓, EZH2↓, miR-34a↑, miR-200c↑, miR-145↑, CSCs↓,
3233- EGCG,    Epigallocatechin gallate inhibits HeLa cells by modulation of epigenetics and signaling pathways
- in-vitro, Cerv, HeLa
DNMTs↓, DNMT1↓, DNMT3A↓, HDAC2↓, HDAC3↓, HDAC4↓, EZH2↓, PI3K↓, Wnt↓, MAPK↓, hTERT/TERT↓, MMP2↓, MMP7↓, IL6↓, MDM2↓, MMP-10↓, TP53↑, PTEN↑,
816- GAR,    Garcinol downregulates Notch1 signaling via modulating miR-200c and suppresses oncogenic properties of PANC-1 cancer stem-like cells
- in-vitro, PC, PANC1
Mcl-1↓, EZH2↓, ABCG2↓, Gli1↓, NOTCH1↓, miR-200c↑,
2891- HNK,    Honokiol, an Active Compound of Magnolia Plant, Inhibits Growth, and Progression of Cancers of Different Organs
- Review, Var, NA
AntiCan↑, Inflam↓, antiOx↑, selectivity↑, *toxicity↓, cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4↓, TumMeta↓, NADPH↓, MMP2↓, MMP9↓, p‑mTOR↓, EGFR↓, EMT↓, SIRT1↑, SIRT3↑, EZH2↓, Snail↓, Vim↓, N-cadherin↓, E-cadherin↑, COX2↓, NF-kB↓, *ROS↓, Ca+2↑, ROS↑,
2927- LT,    Luteolin Causes 5′CpG Demethylation of the Promoters of TSGs and Modulates the Aberrant Histone Modifications, Restoring the Expression of TSGs in Human Cancer Cells
- in-vitro, Cerv, HeLa
TumCMig↓, DNMTs↓, HDAC↓, HATs↓, ac‑H3↓, ac‑H4↓, MMP2↓, MMP9↓, HO-1↓, E-cadherin↑, EZH2↓, HER2/EBBR2↓, IL18↓, IL8↓, IL2↓,
2928- LT,    Luteolin-mediated increase in miR-26a inhibits prostate cancer cell growth and induces cell cycle arrest targeting EZH2
EZH2↓, cycD1/CCND1↓, cycE/CCNE↓, CDK4↓, CDK6↓,
3274- Lyco,    Lycopene enhances the sensitivity of castration-resistant prostate cancer to enzalutamide through the AKT/EZH2/ androgen receptor signaling pathway
- in-vitro, Pca, 22Rv1 - in-vitro, Pca, C4-2B
Akt↓, EZH2↓,
4928- PEITC,    Dietary phytochemical PEITC restricts tumor development via modulation of epigenetic writers and erasers
- vitro+vivo, Colon, SW-620
Risk↓, HDAC↓, TumW↓, TumCG↓, AP-1↓, cAMP↓, NF-kB↓, BMI1↓, SUZ12↓, EZH2↓, selectivity↑,
3359- QC,    Quercetin modifies 5′CpG promoter methylation and reactivates various tumor suppressor genes by modulating epigenetic marks in human cervical cancer cells
- in-vitro, Cerv, HeLa
DNMTs↓, HDAC↓, HMTs↓, DNMT3A↓, EZH2↓, HDAC1↓, HDAC2↓, HDAC6↓, HDAC11↓, G9a↓, TIMP3↑, PTEN↑, SOCS1↑,
54- QC,    Quercetin‑3‑methyl ether suppresses human breast cancer stem cell formation by inhibiting the Notch1 and PI3K/Akt signaling pathways
- in-vitro, BC, MCF-7
EMT↓, E-cadherin↑, Vim↓, MMP2↓, NOTCH1↓, PI3K/Akt↓, PI3k/Akt/mTOR↓, p‑Akt↓, EZH2↓,
3084- RES,    Resveratrol inhibits the proliferation of estrogen receptor-positive breast cancer cells by suppressing EZH2 through the modulation of ERK1/2 signaling
- in-vitro, BC, MCF-7 - in-vitro, BC, T47D
TumCP↓, EZH2↓, p‑ERK↓,
3422- TQ,    Thymoquinone, as a Novel Therapeutic Candidate of Cancers
- Review, Var, NA
selectivity↑, P53↑, PTEN↑, NF-kB↓, PPARγ↓, cMyc↓, Casp↑, *BioAv↓, BioAv↝, eff↑, survivin↓, Bcl-xL↓, Bcl-2↓, Akt↓, BAX↑, cl‑PARP↑, CXCR4↓, MMP9↓, VEGFR2↓, Ki-67↓, COX2↓, JAK2↓, cSrc↓, Apoptosis↑, p‑STAT3↓, cycD1/CCND1↓, Casp3↑, Casp7↑, Casp9↑, N-cadherin↓, Vim↓, Twist↓, E-cadherin↑, ChemoSen↑, eff↑, EMT↓, ROS↑, DNMT1↓, eff↑, EZH2↓, hepatoP↑, Zeb1↓, RadioS↑, HDAC↓, HDAC1↓, HDAC2↓, HDAC3↓, *NAD↑, *SIRT1↑, SIRT1↓, *Inflam↓, *CRP↓, *TNF-α↓, *IL6↓, *IL1β↓, *eff↑, *MDA↓, *NO↓, *GSH↑, *SOD↑, *Catalase↑, *GPx↑, PI3K↓, mTOR↓,

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 18

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 1,   HO-1↓, 1,   HO-1↑, 1,   NQO1↑, 1,   ROS↑, 4,   SIRT3↑, 1,  

Mitochondria & Bioenergetics ⓘ

MMP↓, 1,   XIAP↓, 1,  

Core Metabolism/Glycolysis ⓘ

cAMP↓, 1,   cMyc↓, 1,   NADPH↓, 1,   PI3K/Akt↓, 1,   PI3k/Akt/mTOR↓, 1,   PPARγ↓, 1,   RARβ↑, 1,   SIRT1↓, 2,   SIRT1↑, 1,  

Cell Death ⓘ

Akt↓, 2,   Akt↑, 1,   p‑Akt↓, 1,   Apoptosis↑, 2,   BAX↑, 1,   Bcl-2↓, 3,   Bcl-xL↓, 1,   Casp↑, 1,   Casp3↑, 2,   Casp7↑, 1,   Casp9↑, 2,   hTERT/TERT↓, 2,   MAPK↓, 1,   Mcl-1↓, 1,   MDM2↓, 1,   survivin↓, 1,  

Kinase & Signal Transduction ⓘ

AMPKα↑, 1,   cSrc↓, 1,   HER2/EBBR2↓, 1,   SOX9?, 1,   Sp1/3/4↓, 1,  

Transcription & Epigenetics ⓘ

EZH2↓, 18,   ac‑H3↓, 1,   ac‑H4↓, 1,   HATs↓, 1,   HATs↑, 1,   miR-145↑, 1,   miR-21↓, 1,   miR-27a-3p↓, 1,  

Protein Folding & ER Stress ⓘ

CHOP↑, 1,   ER Stress↑, 1,   GRP78/BiP↑, 1,  

Autophagy & Lysosomes ⓘ

LC3II↓, 1,   TumAuto↑, 1,  

DNA Damage & Repair ⓘ

DNAdam↑, 1,   DNMT1↓, 4,   DNMT3A↓, 3,   DNMTs↓, 4,   G9a↓, 1,   p16↑, 1,   P53↑, 1,   cl‑PARP↑, 1,   TP53↑, 2,  

Cell Cycle & Senescence ⓘ

CDK1↓, 1,   CDK2↓, 1,   CDK4↓, 2,   cycA1/CCNA1↓, 1,   cycD1/CCND1↓, 4,   cycE/CCNE↓, 2,  

Proliferation, Differentiation & Cell State ⓘ

BMI1↓, 2,   CSCs↓, 2,   EMT↓, 4,   p‑ERK↓, 1,   Gli1↓, 1,   HDAC↓, 6,   HDAC1↓, 3,   HDAC11↓, 1,   HDAC2↓, 3,   HDAC3↓, 2,   HDAC4↓, 1,   HDAC6↓, 1,   HDAC8↓, 1,   HMTs↓, 1,   HMTs↑, 1,   miR-34a↑, 1,   mTOR↓, 1,   p‑mTOR↓, 2,   Nanog↓, 1,   NOTCH1↓, 4,   OCT4↓, 1,   PI3K↓, 2,   PTEN↑, 4,   SOX2↓, 1,   STAT3↓, 1,   p‑STAT3↓, 1,   SUZ12↓, 2,   TumCG↓, 1,   Wnt↓, 1,  

Migration ⓘ

AP-1↓, 1,   AXL↓, 1,   Ca+2↑, 2,   CDH1↑, 1,   CXCL12↓, 1,   DLC1↑, 2,   E-cadherin↑, 4,   Ki-67↓, 1,   LAMs↓, 1,   miR-200c↑, 2,   MMP-10↓, 1,   MMP2↓, 5,   MMP7↓, 1,   MMP9↓, 4,   N-cadherin↓, 2,   Snail↓, 1,   TGF-β↓, 1,   TIMP3↑, 1,   TumCMig↓, 1,   TumCP↓, 1,   TumMeta↓, 1,   Twist↓, 1,   Vim↓, 3,   Zeb1↓, 1,   α-SMA↓, 1,  

Angiogenesis & Vasculature ⓘ

ATF4↑, 1,   EGFR↓, 1,   Hif1a↓, 2,   VEGF↓, 2,   VEGFR2↓, 1,   ZBTB10↑, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 2,   CXCR4↓, 1,   IL18↓, 1,   IL2↓, 1,   IL6↓, 2,   IL8↓, 1,   Inflam↓, 1,   JAK2↓, 2,   NF-kB↓, 4,   SOCS1↑, 1,  

Hormonal & Nuclear Receptors ⓘ

CDK6↓, 1,  

Drug Metabolism & Resistance ⓘ

ABCG2↓, 1,   BioAv↓, 1,   BioAv↑, 1,   BioAv↝, 1,   ChemoSen↑, 3,   eff↑, 4,   RadioS↑, 1,   selectivity↑, 3,   TET2↑, 1,  

Clinical Biomarkers ⓘ

EGFR↓, 1,   EZH2↓, 18,   HER2/EBBR2↓, 1,   hTERT/TERT↓, 2,   IL6↓, 2,   Ki-67↓, 1,   SUZ12↓, 2,   TP53↑, 2,  

Functional Outcomes ⓘ

AntiCan↑, 1,   hepatoP↑, 1,   Risk↓, 1,   TumW↓, 1,  
Total Targets: 158

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 1,   Catalase↑, 1,   GPx↑, 1,   GSH↑, 1,   MDA↓, 2,   ROS↓, 3,   SOD↑, 2,  

Core Metabolism/Glycolysis ⓘ

NAD↑, 1,   SIRT1↑, 1,  

Angiogenesis & Vasculature ⓘ

NO↓, 1,   NO↑, 1,  

Immune & Inflammatory Signaling ⓘ

CRP↓, 1,   IL1β↓, 1,   IL6↓, 1,   Inflam↓, 2,   TNF-α↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 1,   eff↑, 1,  

Clinical Biomarkers ⓘ

CRP↓, 1,   IL6↓, 1,  

Functional Outcomes ⓘ

cognitive↑, 1,   memory↑, 1,   toxicity↓, 1,  
Total Targets: 23

Scientific Paper Hit Count for: EZH2, enhancer of zeste homolog 2 (Drosophila)
3 Curcumin
2 Berberine
2 EGCG (Epigallocatechin Gallate)
2 Luteolin
2 Quercetin
1 alpha Linolenic acid
1 Apigenin (mainly Parsley)
1 Sulforaphane (mainly Broccoli)
1 Ursolic acid
1 Gambogic Acid
1 5-fluorouracil
1 Garcinol
1 Honokiol
1 Lycopene
1 Phenethyl isothiocyanate
1 Resveratrol
1 Thymoquinone
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:108  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page